22nd Century (Nasdaq: XXII) Appoints Dr. Calvin Treat as Chief Scientific Officer
BUFFALO, N.Y., April 11, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced the appointment of Dr. Calvin Treat as Chief Scientific Officer, effective May 23, 2022. In this new role, Dr. Treat will lead the expanding scientific, research and technological operations of the company, leveraging its expertise, IP, and partnerships across all three of its alkaloid plant franchises toward becoming a global leader in specialty plant science.
- BUFFALO, N.Y., April 11, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced the appointment of Dr. Calvin Treat as Chief Scientific Officer, effective May 23, 2022.
- Treat brings a wealth of plant-based biotechnology and crop technology experience to 22nd Century at a pivotal time when we are rapidly expanding our global capabilities across all three of our alkaloid plant franchises tobacco, hemp/cannabis, and hops, said James A. Mish, chief executive officer of 22nd Century Group.
- Treat has spent his career at the largest plant science names in the world, leading their innovations on major crops like corn, soybeans, and cotton.
- 22nd Century Group, Inc. (Nasdaq: XXII ) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science.